{"id":"https://openalex.org/W4249199995","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.3001","title":"First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers.","display_name":"First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers.","publication_year":2010,"publication_date":"2010-05-20","ids":{"openalex":"https://openalex.org/W4249199995","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.3001"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2010.28.15_suppl.3001","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.3001","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.3001","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5075464784","display_name":"S. K. Sandhu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. K. Sandhu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040661254","display_name":"R. M. Wenham","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. M. Wenham","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061697254","display_name":"George Wilding","orcid":"https://orcid.org/0009-0000-5775-5293","observed_orcids":["https://orcid.org/0009-0000-5775-5293"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. Wilding","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085365387","display_name":"M. McFadden","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. McFadden","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013286355","display_name":"L. Sun","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L. Sun","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015441971","display_name":"Carlo Toniatti","orcid":"https://orcid.org/0000-0001-9493-344X","observed_orcids":["https://orcid.org/0000-0001-9493-344X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Toniatti","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065576438","display_name":"M. Stroh","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Stroh","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"C. L. Carpenter","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. L. Carpenter","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072378199","display_name":"Johann Sebastian De Bono","orcid":"https://orcid.org/0000-0002-2034-595X","observed_orcids":["https://orcid.org/0000-0002-2034-595X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. S. De Bono","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5065117747","display_name":"W. R. Schelman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. R. Schelman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":34,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"28","issue":"15_suppl","first_page":"3001","last_page":"3001"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.796999990940094},{"id":"https://openalex.org/keywords/parp1-2-inhibition","display_name":"PARP1/2 inhibition","score":0.8230000138282776},{"id":"https://openalex.org/keywords/sporadic-ovarian-cancer","display_name":"sporadic ovarian cancer","score":0.949999988079071},{"id":"https://openalex.org/keywords/homologous-recombination-deficiency","display_name":"homologous recombination deficiency","score":0.8009999990463257},{"id":"https://openalex.org/keywords/synthetic-lethality","display_name":"synthetic lethality","score":0.9819999933242798},{"id":"https://openalex.org/keywords/brca1-2-mutation-carriers","display_name":"BRCA1/2 mutation carriers","score":0.6769999861717224},{"id":"https://openalex.org/keywords/serous-ovarian-cancer","display_name":"serous ovarian cancer","score":0.7820000052452087},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.7179999947547913},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8090000152587891},{"id":"https://openalex.org/keywords/pneumonitis","display_name":"pneumonitis","score":0.8410000205039978},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8420000076293945},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.7760000228881836},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.7940000295639038},{"id":"https://openalex.org/keywords/first-in-human","display_name":"first-in-human","score":0.8009999990463257}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8943469524383545},{"id":"https://openalex.org/C2779138821","wikidata":"https://www.wikidata.org/wiki/Q7118227","display_name":"PARP inhibitor","level":5,"score":0.6558701992034912},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5534720420837402},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5170400738716125},{"id":"https://openalex.org/C2780427987","wikidata":"https://www.wikidata.org/wiki/Q172341","display_name":"Ovarian cancer","level":3,"score":0.5109133124351501},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4781852066516876},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.47355523705482483},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.46718695759773254},{"id":"https://openalex.org/C2779962180","wikidata":"https://www.wikidata.org/wiki/Q7083106","display_name":"Olaparib","level":5,"score":0.44824275374412537},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.43598994612693787},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.41489630937576294},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3567742109298706},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.32002967596054077},{"id":"https://openalex.org/C182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","level":4,"score":0.27276796102523804},{"id":"https://openalex.org/C82381507","wikidata":"https://www.wikidata.org/wiki/Q416878","display_name":"Polymerase","level":3,"score":0.09806665778160095},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2010.28.15_suppl.3001","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.3001","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.3001","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2276971282","https://openalex.org/W2171474267","https://openalex.org/W15193367","https://openalex.org/W2128746885","https://openalex.org/W2033108966","https://openalex.org/W2160399783","https://openalex.org/W2599038431","https://openalex.org/W2050050592","https://openalex.org/W2061827661","https://openalex.org/W2171972386"],"abstract_inverted_index":{"3001":[0],"Background:":[1],"MK-4827":[2,14,163,304],"is":[3,176,305],"a":[4,118,181,247],"potent,":[5],"selective,":[6],"PARP":[7,194,309],"1/2":[8],"inhibitor":[9],"with":[10,26,33,62,180,219,249,265,277,288],"IC50":[11],"of":[12,52,117,185,203],"3.8nM.":[13],"induces":[15],"selective":[16],"synthetic":[17],"lethality":[18],"in":[19,40,50,123,134,141,149,157,196,211,262,315],"homologous":[20],"recombination":[21],"(HR)":[22],"repair":[23,64],"deficient":[24],"tumors":[25],"BRCA1/2":[27],"loss":[28],"and":[29,58,74,154,171,214,241,257,274,310,318],"tumor":[30],"cell":[31,292],"lines":[32],"non-BRCA-related":[34],"HR":[35,63],"defects,":[36],"supporting":[37],"clinical":[38],"utility":[39],"sporadic":[41,59,213,236,266,319],"tumors.":[42],"Methods:":[43],"MK4827":[44],"was":[45,68,132,209,260],"administered":[46],"orally":[47],"once":[48],"daily":[49],"cohorts":[51],"3-6":[53],"pts,":[54],"enriched":[55],"for":[56,229,270,282,299],"BRCA-deficient":[57,215,243,250,278,317],"cancers":[60],"associated":[61],"defects.":[65],"Dose":[66],"escalation":[67],"guided":[69],"by":[70,126],"toxicity,":[71],"pharmacokinetic":[72],"(PK)":[73],"pharmacodynamic":[75],"(PD)":[76],"data.":[77],"Results:":[78],"39":[79],"pts":[80,143,151,159,218,276],"(male":[81],"10,":[82],"female":[83],"29;":[84],"median":[85],"age":[86],"58":[87],"years;":[88],"11":[89],"BRCA":[90],"mutation":[91],"carriers)":[92],"were":[93],"treated":[94],"at":[95,144,152,160,201],"7":[96],"successive":[97],"dose":[98,178],"levels":[99],"[30mg":[100],"(6),":[101,107,111],"40mg":[102],"(3),":[103],"60mg":[104],"(7),":[105],"80mg":[106],"110mg":[108],"(5),":[109],"150mg":[110],"210mg":[112],"(6)]":[113],"on":[114],"days":[115],"1-21":[116],"28":[119],"day":[120],"cycle":[121],"(C)":[122],"C1,":[124],"followed":[125],"continuous":[127],"dosing.":[128],"Overall,":[129],"dose-limiting":[130],"toxicity":[131],"observed":[133,210],"3":[135,139,217],"pts:":[136],"grade":[137],"(G)":[138],"fatigue":[140],"1/6":[142,150,158],"30mg,":[145],"reversible":[146,166],"G3":[147,155],"pneumonitis":[148],"60mg,":[153],"anorexia":[156],"210mg.":[161],"Other":[162,338],"related":[164],"G1-2":[165],"adverse":[167],"events":[168],"include":[169],"nausea":[170],"myelosuppression.":[172],"Preliminary":[173],"PK":[174],"data":[175],"approximately":[177],"proportional":[179],"mean":[182],"terminal":[183],"t1/2":[184],"40":[186],"hours":[187],"(range":[188],"27-57).":[189],"PD":[190],"studies":[191],"confirmed":[192],"consistent":[193],"inhibition":[195],"peripheral":[197],"blood":[198],"mononuclear":[199],"cells":[200],"doses":[202],">":[204,271,283,300],"110":[205],"mg.":[206],"Antitumor":[207],"activity":[208,314],"both":[212,316],"cancers.":[216,320],"serous":[220,267,279],"ovarian":[221,239,244,268,280],"cancer":[222,240,252,269,281,294],"had":[223,253],"prolonged":[224],"RECIST":[225],"partial":[226],"responses":[227],"(PR)":[228],"17+,":[230],"22+,":[231],"44+":[232],"weeks":[233],"(w)":[234],"(1":[235],"platinum":[237],"sensitive":[238],"2":[242,275],"cancers).":[245],"Furthermore,":[246],"patient":[248,264,287],"breast":[251],"an":[254],"unconfirmed":[255],"PR":[256],"disease":[258,298],"stabilization":[259],"seen":[261],"1":[263,286],"44":[272],"w":[273],"16":[284],"w.":[285,302],"heavily":[289],"pretreated":[290],"non-small":[291],"lung":[293],"has":[295,311],"ongoing":[296],"stable":[297],"42":[301],"Conclusions:":[303],"well":[306],"tolerated,":[307],"blocks":[308],"promising":[312],"antitumor":[313],"Author":[321],"Disclosure":[322],"Employment":[323],"or":[324,328],"Leadership":[325],"Position":[326],"Consultant":[327],"Advisory":[329],"Role":[330],"Stock":[331],"Ownership":[332],"Honoraria":[333],"Research":[334],"Funding":[335],"Expert":[336],"Testimony":[337],"Remuneration":[339],"Merck":[340,341,342,343,344]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":5},{"year":2012,"cited_by_count":5}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2022-05-12T00:00:00"}